Canopy Immuno-Therapeutics

About

Funding history · 2 rounds · — total

Q&A

What is Canopy Immuno-Therapeutics' primary focus?

Canopy Immuno-Therapeutics is a pre-clinical stage biotech company focused on developing a new class of biologics for the elimination of antigen-specific immunity, aiming to provide non-immunosuppressive treatments for autoimmune, allergic, and other antibody-mediated conditions using its proprietary Reverse-Immunization platform.

When was Canopy Immuno-Therapeutics founded?

Canopy Immuno-Therapeutics was founded in December 2019.

What is the current employee count for Canopy Immuno-Therapeutics?

Canopy Immuno-Therapeutics has 6 employees, falling within the 1-10 employee bucket.

Which investors participated in Canopy Immuno-Therapeutics' funding round in February 2024?

TLV Partners participated in Canopy Immuno-Therapeutics' funding round in February 2024.

What is Canopy Immuno-Therapeutics' current funding stage?

Canopy Immuno-Therapeutics is currently in its Series A funding stage.

What sector does Canopy Immuno-Therapeutics primarily operate in?

Canopy Immuno-Therapeutics' primary sector is Health Tech & Life Sciences, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development.

What is the product stage of Canopy Immuno-Therapeutics?

Canopy Immuno-Therapeutics' product is currently in the R&D stage.

What technologies does Canopy Immuno-Therapeutics utilize?

Canopy Immuno-Therapeutics utilizes Platforms & Interfaces, Software, and Artificial Intelligence technologies.

Team · 1

Kfir Oved

Founder · Founder & CEO

Sectors & technology

Highlights

Tags